Journal ArticleDOI
Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document
Reads0
Chats0
TLDR
The human response evaluation criteria in solid tumours is used as a framework to establish standard procedures for response assessment in canine solid tumour assessment that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in veterinary oncology.Abstract:
In veterinary medical oncology, there is currently no standardized protocol for assessing response to therapy in solid tumours. The lack of such a formalized guideline makes it challenging to critically compare outcome measures across various treatment protocols. The Veterinary Cooperative Oncology Group (VCOG) membership consensus document presented here is based on the recommendations of a subcommittee of American College of Veterinary Internal Medicine (ACVIM) board-certified veterinary oncologists. This consensus paper has used the human response evaluation criteria in solid tumours (RECIST v1.1) as a framework to establish standard procedures for response assessment in canine solid tumours that is meant to be easy to use, repeatable and applicable across a variety of clinical trial structures in veterinary oncology. It is hoped that this new canine RECIST (cRECIST v1.0) will be adopted within the veterinary oncology community and thereby facilitate the comparison of current and future treatment protocols used for companion animals with cancer.read more
Citations
More filters
Journal ArticleDOI
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Naoya Maekawa,Satoru Konnai,Satoshi Takagi,Yumiko Kagawa,Tomohiro Okagawa,Asami Nishimori,Ryoyo Ikebuchi,Yusuke Izumi,Tatsuya Deguchi,Chie Nakajima,Yukinari Kato,Keiichi Yamamoto,Hidetoshi Uemura,Yasuhiko Suzuki,Shiro Murata,Kazuhiko Ohashi +15 more
TL;DR: In this paper, the authors evaluated the immunomodulatory effects of a canine chimerised anti-PD-L1 monoclonal antibody (c4G12) in vitro, demonstrating significantly enhanced cytokine production and proliferation of dog peripheral blood mononuclear cells.
Journal ArticleDOI
Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial
Robert J. Canter,Steven K. Grossenbacher,Jennifer A. Foltz,Ian R. Sturgill,Jiwon Sarah Park,Jesus I. Luna,Michael S. Kent,William T. N. Culp,Mingyi Chen,Jaime F. Modiano,Arta M. Monjazeb,Dean A. Lee,William J. Murphy +12 more
TL;DR: NK cell homing and cytotoxicity are increased following RT in canine models of sarcoma, and results from a first-in-dog clinical trial for spontaneous osteosarcoma are promising, including possible abscopal effects.
Journal ArticleDOI
Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?
TL;DR: Resources that are currently available to study canine lymphoma, advantages to be gained by exploiting the genetic breed structure in dogs, and current and future challenges and opportunities to take full advantage of this resource for lymphoma studies are described.
Journal ArticleDOI
Defining the Value of a Comparative Approach to Cancer Drug Development
TL;DR: This review seeks to demonstrate types of drug development questions that are best answered by the comparative oncology approach, and contends that it is reasonable to consider these data as potentially informative and valuable to cancer drug development, but as supplementary to conventional preclinical studies and human clinical trials.
Journal ArticleDOI
2016 AAHA Oncology Guidelines for Dogs and Cats.
Barb Biller,John Berg,Laura D. Garrett,David M. Ruslander,Richard Wearing,Bonnie Abbott,Mithun Patel,Diana M. Smith,Christine Bryan +8 more
TL;DR: These guidelines discuss the strict safety precautions that should be observed in handling chemotherapy agents, which are now commonly used in veterinary oncology, and include comprehensive tables of common canine and feline cancers as a resource for case management and a sample case history.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Reporting results of cancer treatment.
TL;DR: Recommendations have been developed for standardized approaches to the recording of baseline data relating to the patient, the tumor, laboratory and radiologic data, the reporting of treatment, grading of acute and subacute toxicity, reporting of response, recurrence and disease‐free interval, and reporting results of therapy.
Journal Article
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
Hirokazu Watanabe,Morihito Okada,Yasushi Kaji,Miyako Satouchi,Yozo Sato,Yuichiro Yamabe,Hiroaki Onaya,Masahiro Endo,Miyuki Sone,Yasuaki Arai +9 more
TL;DR: This paper is an overview of the new response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), with a focus on updated contents.
Journal ArticleDOI
Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.
TL;DR: These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal).
Journal ArticleDOI
Individual patient data analysis to assess modifications to the RECIST criteria.
Jan Bogaerts,Robert Ford,Daniel J. Sargent,Lawrence H. Schwartz,Larry Rubinstein,Denis Lacombe,Elizabeth Eisenhauer,Jaap Verweij,P. Therasse +8 more
TL;DR: Assessment of 5 lesions per patient led to a difference in best overall response assignment for an estimated 209 patients as compared to RECIST version 1.0, but removal of the requirement for response confirmation did not affect the overall response rate.
Related Papers (5)
Toxicity criteria of the veterinary radiation therapy oncology group.
Tracy A. LaDue,Mary K. Klein +1 more